Physician profile
Mir Khan
NPI 1669448080
$437.45
in general payments reported to CMS, 2019-2025
15 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.36 · 2020: $31.18 · 2021: $27.15 · 2022: $90.39 · 2023: $16.53 · 2024: $115 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $108.03 | 2019-2024 | |
| Abbvie INC. | $89.94 | 2021-2025 | |
| Smith+Nephew, INC. | $28.56 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $28.18 | 2022-2024 | Lokelma |
| Novo Nordisk INC | $24.27 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.31 | 2025 | Caplyta |
| Celgene Corporation | $17.57 | 2019 | |
| Currax Pharmaceuticals LLC | $17.17 | 2025 | Contrave |
| Lundbeck LLC | $17.02 | 2025 | Rexulti |
| Lilly USA, LLC | $16.53 | 2023 | Mounjaro |
| Abiomed | $15.29 | 2024 | Impella |
| Esperion Therapeutics, INC. | $15.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.15 | 2020 | |
| Solventum Corporation | $13.92 | 2025 | Activ.A.C. |
| Janssen Pharmaceuticals, INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.